Compare Essex Property Trust, Inc. (ESS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Viatris Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Essex Property Trust, Inc. and Viatris Inc are close in size by market cap, and Essex Property Trust, Inc. pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ESS | VTRS | |
|---|---|---|
Market Cap | $18.15B | $18.69B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $17.86 |
52-Week Low | $239.61 | $9.49 |
Enterprise Value | $24.75B | $30.80B |
Dividend Yield | 3.93% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
